How ALK4 signaling affects bone health and disease
The role of ALK4 signaling in skeletal homeostasis and pathogenesis
This research looks at whether changing ALK4-related signaling affects bone strength and could help adults whose bones are weakened by chronic illnesses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard Medical School NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11238880 on NIH RePORTER |
What this research studies
From a patient perspective, researchers will use lab experiments and animal models to find which bone cells respond when ALK4 and related signals are blocked. They will study ligand-trap molecules (similar to drugs already being tested for diabetes, arthritis, and other chronic conditions) and use genetic approaches to remove Alk4 in targeted cells to see how bone mass and strength change. The team will analyze molecular pathways like Smad2/3 to understand how these changes happen and to predict possible bone side effects. Results are intended to guide safer use of emerging TGF-β pathway therapies in people with chronic diseases that affect the skeleton.
Who could benefit from this research
Good fit: Adults with chronic conditions that affect bone health—such as type 2 diabetes, rheumatoid arthritis, chronic inflammatory anemia, or cancer-related cachexia—would be the most relevant group for findings from this work.
Not a fit: People without bone-related complications or whose care does not involve TGF-β/ligand-trap therapies are unlikely to receive direct benefit from this grant.
Why it matters
Potential benefit: If successful, this work could help prevent or reduce bone loss caused by new ligand-trap therapies and guide safer use of these treatments for people with chronic illnesses.
How similar studies have performed: Preclinical studies using Acvr2A/B ligand traps have shown improved bone mass and strength in mice and ligand-trap therapies are in clinical trials for several chronic diseases, but ALK4's specific role in bone responses is a newer area of study.
Where this research is happening
Boston, United States
- Harvard Medical School — Boston, United States (Active)
Researchers
- Principal investigator: Rosen, Vicki — Harvard Medical School
- Study coordinator: Rosen, Vicki
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.